Stratagene Shares Continue Descent | GenomeWeb

Shares in Stratagene fell 3.1 percent for the trading week ended Tuesday. The decline followed last week's drop of 23.3 percent, but the reasons for its fall remain unclear. Stratagene's shares finished Tuesday at $7.16 hovering above a 52-week low of $6.42 reached last September. Bruker led gainers for the week with a 6.3-percent rise.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.